Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients

References

• Sung H, Ferlay J, Siegel RL., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. doi:10.1038/35021093
   PubMed Web of Science ®Google Scholar
• Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167. doi:10.1200/JCO.2008.18.1370
   PubMed Web of Science ®Google Scholar
• Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21(2):250–260. doi:10.1016/S1470-2045(19)30804-6
   PubMed Web of Science ®Google Scholar
• Pedersen AC, Sorensen PD, Jacobsen EH, Madsen JS, Brandslund I. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Clin Chem Lab Med. 2013;51(7):1511–1519. doi:10.1515/cclm-2012-0488
   PubMed Web of Science ®Google Scholar
• Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012;38(2):133–142. doi:10.1016/j.ctrv.2011.03.008
   PubMed Web of Science ®Google Scholar
• Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999;59(6):1196–1201.
   PubMed Web of Science ®Google Scholar
• Pichon MF, Hacene K, Guepratte S, Neumann R. Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients. Clin Lab. 2004;50(3–4):163–170.
   PubMedGoogle Scholar
• Ryu DW, Lee CH. Impact of serum HER2 levels on survival and its correlation with clinicopathological parameters in women with breast cancer. J Breast Cancer. 2012;15(1):71–78. doi:10.4048/jbc.2012.15.1.71
   PubMed Web of Science ®Google Scholar
• Kong Y, Dai S, Xie X, et al. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol. 2012;138(2):275–284. doi:10.1007/s00432-011-1095-9
   PubMed Web of Science ®Google Scholar
• Carney WP, Bernhardt D, Jasani B. Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer. 2013;5:31–39. doi:10.4137/BIC.S12389
   PubMedGoogle Scholar
• Lee MH, Jung SY, Kang SH, et al. The significance of serum HER2 levels at diagnosis on intrinsic subtype-specific outcome of operable breast cancer patients. PLoS One. 2016;11(10):e0163370. doi:10.1371/journal.pone.0163370
   PubMed Web of Science ®Google Scholar
• Lipton A, Ali SM, Leitzel K, et al. Elevated Serum HER-2/ neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20(6):1467–1472. doi:10.1200/JCO.2002.20.6.1467
   PubMed Web of Science ®Google Scholar
• Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009;27(10):1685–1693. doi:10.1200/JCO.2008.16.8351
   PubMed Web of Science ®Google Scholar
• Zhang P, Xiao J, Ruan Y, Zhang Z, Zhang X. Monitoring value of serum HER2 as a predictive biomarker in patients with metastatic breast cancer. Cancer Manag Res. 2020;12:4667–4675. doi:10.2147/CMAR.S254897
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study. J Clin Oncol. 2020;38(17):1887–1896. doi:10.1200/JCO.19.02318
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. doi:10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113(7):808–819. doi:10.1093/jnci/djaa201
   PubMedGoogle Scholar
• Cook GB, Neaman IE, Goldblatt JL, et al. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res. 2001;21(2B):1465–1470.
   PubMed Web of Science ®Google Scholar
• Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/ neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008;113(6):1294–1301. doi:10.1002/cncr.23689
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li C, Fan H, et al. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2018;172:513–521.
   PubMed Web of Science ®Google Scholar
• Darlix A, Lamy PJ, Lopez-Crapez E, et al. Serum HER2 extra-cellular domain, S100ss and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016;16(1):428. doi:10.1186/s12885-016-2448-1
   PubMedGoogle Scholar
• Panis C, Pizzatti L, Correa S, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357(1):186–195. doi:10.1016/j.canlet.2014.11.029
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–1161. doi:10.1016/S1470-2045(21)00301-6
   PubMed Web of Science ®Google Scholar
• Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer. 2008;122(5):999–1004. doi:10.1002/ijc.23051
   PubMed Web of Science ®Google Scholar
• Aurilio G, Sandri MT, Pruneri G, et al. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncol. 2016;12(17):2001–2008. doi:10.2217/fon-2016-0081
   PubMed Web of Science ®Google Scholar
• Darlix A, Hirtz C, Thezenas S, et al. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. BMC Cancer. 2019;19(1):110. doi:10.1186/s12885-019-5287-z
   PubMedGoogle Scholar
• Schondorf T, Hoopmann M, Warm M, et al. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin Chem. 2002;48(8):1360–1362. doi:10.1093/clinchem/48.8.1360
   PubMed Web of Science ®Google Scholar
• Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9(12):4423–4434.
   PubMed Web of Science ®Google Scholar
• Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012;1826(1):199–208. doi:10.1016/j.bbcan.2012.03.012
   PubMed Web of Science ®Google Scholar
• Darlix A, Lamy PJ, Lopez-Crapez E, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? Int J Cancer. 2016;139(10):2299–2311. doi:10.1002/ijc.30290
   PubMed Web of Science ®Google Scholar
• Di Gioia D, Dresse M, Mayr D, et al. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014;430:86–91. doi:10.1016/j.cca.2013.12.036
   PubMed Web of Science ®Google Scholar
• Garoufali A, Kyriakou F, Kountourakis P, et al. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON. 2008;13(3):409–413.
   PubMed Web of Science ®Google Scholar
• Lipton A, Leitzel K, Ali SM, et al. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 2011;117(21):5013–5020. doi:10.1002/cncr.26101
   PubMed Web of Science ®Google Scholar
• Moreno-Aspitia A, Hillman DW, Dyar SH, et al. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831. Cancer. 2013;119(15):2675–2682. doi:10.1002/cncr.28130
   PubMed Web of Science ®Google Scholar
• Reix N, Malina C, Chenard MP, et al. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Breast Cancer Res Treat. 2016;160(2):249–259. doi:10.1007/s10549-016-4000-z
   PubMed Web of Science ®Google Scholar
• Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized Phase III study. J Clin Oncol. 2009;27(33):5552–5558. doi:10.1200/JCO.2008.21.1763
   PubMed Web of Science ®Google Scholar
• Shao X, Wang X, Xu X, et al. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer. Int J Clin Exp Pathol. 2014;7:1108–1113.
   PubMed Web of Science ®Google Scholar
• Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005;16:234–239.
   PubMed Web of Science ®Google Scholar